Can the CanRisk tool be used in cases of Ductal Carcinoma-In-Situ (DCIS)?

Owned by Tim Carver

Last updated: Apr 04, 2022 by Alex Cunningham PhD (Unlicensed)

Currently the tool should not be used to calculate the risk of a subsequent (invasive) breast cancer in someone who has DCIS.

DCIS is a risk factor for invasive breast cancer but the risk of invasive breast cancer depends on the type of treatment for DCIS. Neither history of DCIS nor treatment are currently considered in BOADICEA/CanRisk. As a result, BOADICEA/CanRisk should not be used to predict risks in women who have already had a DCIS diagnosis.